With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
|Articles|December 2, 2016
Rheumatoid Arthritis Biosimilar Development Highlights Week in Specialty Pharmacy
Author(s)Davy James, Managing Editor
Top news of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/rheumatoid-arthritis-biosimilar-development-highli" target="_blank">View the story "Rheumatoid Arthritis Biosimilar Development Highlights Week in Specialty Pharmacy" on Storify</a>]
Advertisement
Related to this article
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5